Last reviewed · How we verify

NCT05039008

Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy

Completed NA Last updated 9 February 2024
What this trial tests

NA trial testing Blood flow restriction in Hemophilia in 23 participants. Completed in 21 December 2023.

Timeline
6 September 2023
Primary endpoint
14 November 2023
21 December 2023

Quick facts

Lead sponsorInvestigación en Hemofilia y Fisioterapia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment23
Start date6 September 2023
Primary completion14 November 2023
Estimated completion21 December 2023
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Investigación en Hemofilia y Fisioterapia

Who can join

Adults 18 to 65, male only, with Hemophilia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy. Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in the perception of muscle activation and strength, functionality, joint pain, joint status and the perception of quality of life in patients with hemophilic arthropathy. knee and ankle. Study design. Randomized, multicenter, single-blind clinical study. Method. 20patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 3 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and range of motion (goniometer). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks. Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength, joint pain, range of motion, and joint damage in patients with hemophilic knee and ankle arthropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood flow restriction

Trials testing the same drug.

Other recruiting trials for Hemophilia

Currently open trials in the same condition.

Other Investigación en Hemofilia y Fisioterapia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05039008.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing